GlassScriptPhysician profile
Amanda C Rutherford
NPI 1518100908
$6,722.15
in general payments reported to CMS, 2019-2025
35 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.00 · 2022: $185 · 2023: $800 · 2024: $2,842 · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,688 · Travel and Lodging: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,688.30 |
| Travel and Lodging | $822.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $822.96 | 2024 | Vns Therapy |
| Ucb, INC. | $783.34 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $469.91 | 2023-2025 | |
| Neurelis, INC. | $428.80 | 2023-2025 | Valtoco |
| Emd Serono, INC. | $417.98 | 2023-2025 | Mavenclad |
| Abbvie INC. | $403.07 | 2023-2025 | |
| Genentech USA, INC. | $337.14 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $301.85 | 2023-2025 | |
| Argenx US, INC. | $273.21 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $268.80 | 2023-2025 | Spinraza, Qalsody, Skyclarys |
| Neurocrine Biosciences, INC. | $238.04 | 2023-2025 | Ingrezza |
| Pfizer INC. | $212.06 | 2023-2025 | |
| Sk Life Science, INC. | $207.86 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $205.94 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Mallinckrodt Hospital Products INC. | $190.59 | 2023-2025 | Acthar |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $165.28 | 2023-2025 | Vyepti |
| Janssen Biotech, INC. | $164.78 | 2021-2023 | Symtuza |
| Teva Pharmaceuticals USA, INC. | $133.96 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $128.22 | 2023-2025 | Ultomiris, Soliris |
| Gilead Sciences, INC. | $68.62 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $64.29 | 2024 | Aptiom |
| Upsher-Smith Laboratories LLC | $59.46 | 2024 | |
| Genzyme Corporation | $57.71 | 2023-2025 | |
| Lilly USA, LLC | $48.76 | 2024-2025 | Kisunla |
| Merck Sharp & Dohme LLC | $44.86 | 2022-2023 | Pifeltro, Delstrigo |
| Cycle Pharmaceuticals INC | $43.87 | 2025 | Tascenso Odt, Bafiertam |
| Amneal Pharmaceuticals LLC | $31.23 | 2024 | Rytary |
| Jazz Pharmaceuticals INC. | $24.33 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.96 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $18.74 | 2025 | Uplizna |
| Immedica Pharma US, INC. | $18.06 | 2023 | |
| Tg Therapeutics, INC. | $17.61 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.26 | 2024 | Keveyis |
| Tanabe Pharma America, INC. | $16.03 | 2024 | |
| Novo Nordisk INC | $15.57 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Rutherford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.